Products Pralatrexate is commercially available as an infusion solution (Folotyn). It has been approved in many countries since 2013. Structure and properties Pralatrexate (C23H23N7O5, Mr = 477.5 g/mol) is a folic acid analog and exists as a racemate. It is a white to yellow substance that is soluble in water. Effects Pralatrexate (ATC L01BA05) has … Pralatrexate
Products Imiglucerase is commercially available as a powder for the preparation of an infusion solution (Cerezyme). It has been approved in many countries since 1999. Structure and properties Imiglucerase is an enzyme produced by biotechnological methods. The glycoprotein consists of 497 amino acids. The sequence differs in one amino acid from the natural acid beta-glucocerebrosidase. … Imiglucerase
Products Imipenem is commercially available as an infusion preparation and fixed combination with cilastatin (Tienam, generics). Imipenem was approved in many countries in 1985 as the first member of the carbapenems. Structure and properties Imipenem (C12H17N3O4S, Mr = 299.3 g/mol) is present in drugs as imipenem monohydrate, a white or pale yellow powder that is … Imipenem
Products Human alpha1-proteinase inhibitor was approved in many countries in 2016 as a powder and solvent for the preparation of an intravenous infusion solution (Respreeza, USA: Zemaira). It has been approved in the United States since 2003 and in the EU since 2015. Structure and properties Human alpha1-proteinase inhibitor is a glycoprotein derived from human … Human Alpha1-Proteinase Inhibitor
Products Naloxone is commercially available as a solution for injection (Naloxone OrPha, Naloxone Actavis) and has been approved in many countries since 2004. Information on combination with oxycodone is presented under the article Oxycodone and Naloxone (Targin, Peroral). As a fixed combination with buprenorphine, naloxone is used to treat opioid dependence (Suboxone, sublingual). In 2014, … Naloxone
Products Naloxone nasal spray was approved in the United States in 2015 (Narcan), in the EU in 2017, and in many countries in 2018 (Nyxoid). Each nasal spray contains only one dose and can be used only once. Structure and properties Naloxone (C19H21NO4, Mr = 327.37 g/mol) is a semisynthetic derivative of morphine. It is … Naloxone Nasal Spray
Products Epinephrine is commercially available as an injection solution and as an epinephrine auto-injector from various suppliers. The active ingredient is also known as epinephrine, especially in English (in German: Epinephrin). Structure and properties Epinephrine (C9H13NO3, Mr = 183.2 g/mol) exists as a white, crystalline powder with a bitter taste that turns brownish on contact … Adrenaline
Products Aducanumab has been studied in phase III trials and is in the pre-approval phase. The drug is not yet commercially available. The trials were discontinued in March 2019. However, following a re-analysis, the company announced in October 2019 that it expected to file for approval. Apparently, a sufficiently high dose is required for an … Aducanumab
Products Agalsidase is commercially available as an infusion preparation and has been approved in many countries since 2001 and 2003, respectively: Replagal: agalsidase alfa Fabrazyme: agalsidase beta Structure and properties Agalsidase is a recombinant human α-galactosidase A produced by biotechnological methods. The amino acid sequence is identical to the natural lysosomal enzyme. It is a … Agalsidase
Products Avelumab was approved in the United States, the EU, and many countries in 2017 as a concentrate for the preparation of an infusion solution (Bavencio). Structure and properties Avelumab is a human IgG1λ monoclonal antibody against programmed cell death ligand 1 (PD-L1) with a molecular weight of 147 kDa. It is produced by biotechnological … Avelumab
Products Avibactam was approved in the United States in 2015, in the EU in 2016, and in many countries in 2019 in fixed combination with the cephalosporin ceftazidime as a powder for a concentrate for solution for infusion (Zavicefta). Structure and properties Avibactam (C7H11N3O6S, Mr = 265.25 g/mol), unlike other beta-lactamase inhibitors, is not itself … Avibactam
Products Delafloxacin was approved in the United States in 2017, in the EU in 2019, and in many countries in 2020 as a powder for a concentrate for solution for infusion and in tablet form (Quofenix). Structure and properties Delafloxacin (C18H12ClF3N4O4, Mr = 440.8 g/mol) belongs to the group of fluoroquinolones. It is present in … Delafloxacin
